Colorectal Cancer Awareness Month: Dr. Christopher Lieu on ctDNA, BESPOKE, GALAXY, and NETTER-2

Christopher Lieu, MD, University of Colorado Cancer Center, discusses some of the latest updates in circulating tumor DNA (ctDNA) and radioligand therapy research in colorectal cancer, giving an overview of the BESPOKE trial and the GALAXY arm of the CIRCULATE-Japan study on the utilization of ctDNA as a biomarker for adjuvant chemotherapy treatment and to detect early disease progression during surveillance.

Dr. Lieu also gives a review of the NETTER-2 trial, which examined the use of 177Lu in patients with gastroenteropancreatic neuroendocrine tumors; the first randomized study to analyze radioligand therapy in the first-line setting for any malignancy.